Navigation Links
VolitionRx-led Consortium Awarded euro 780 000 ($1M approx.) Eurostars Grant
Date:9/3/2013

NAMUR, Belgium, Sept. 3, 2013 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, is lead partner of a consortium in a project valued at €779,493 (approx. US$1M) under the EUREKA Eurostars scheme. The project aims to develop new applications of the Nucleosomics biomarker technology in inflammatory disease. The research will build on VolitionRx's ongoing cancer diagnostic research program.

VolitionRx's contribution to the project is to develop novel NuQ® biomarkers for immune response. VolitionRx will use its proprietary Nucleosomics® platform for biomarker development exploiting UK-based Alcyomics' proprietary ex-vivo Skimmune™ model.

The Eurostars Programme is a European innovation program managed by EUREKA. It is the first program dedicated to supporting research-based small- and medium-sized companies (SMEs) from across Europe. To be eligible for the grant, companies must form a consortium of at least two companies from different European countries, with the aim of developing a civilian-purposed new product, process or service.

"The Eurostars scheme is a prestigious European program designed to support SMEs like VolitionRx, and to encourage cross-border research and development collaboration," says Mark Eccleston, VolitionRx's External Collaborations Manager. "We are looking forward to working with our partners to develop novel applications for our Nucleosomics technology, while complementing our ongoing research in cancer diagnostics."

Under the grant, VolitionRx will be reimbursed with 80% of the costs associated with its share of the joint project  - €420,000 ($0.56M approx.) over two years.

About VolitionRx
VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

Visit Volition's website (www.volitionrx.com) or connect with them via Twitter, LinkedIn or Facebook

About Alcyomics
Our mission at Alcyomics Ltd is to provide novel solutions for pre-clinical drug safety and efficacy testing for therapeutics including cellular therapies and extend our technologies for use in the chemical and cosmetic industries. As a service provider we aspire to take the lead in providing unique screening services using human  in vitro skin explant assays  of value to customers in the Pharma, Cosmetic and Chemical industries enabling more cost effective commercialisation of products and or drugs.

Visit Alcyomics website (http://www.alcyomics.com) or connect with us via Twitter, LinkedIn or Facebook.

Forward-Looking Statements: Statements in this press release may be "forward-looking statements". Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE VolitionRx Limited
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Elsevier Announces its Collaboration with Hungarian National Consortium
2. Pfizer, GSK, and Siemens Form R&D Consortium With A*STARs Institute of Chemical & Engineering Sciences
3. Herbal Quality Consortium Publishes Major Article on Black Cohosh Adulteration
4. Elekta and Philips Gain MD Anderson Cancer Center as Collaborator in Research Consortium on MRI-Guided Radiation Therapy
5. Some Bilberry Fruit Extracts Adulterated, says Nonprofit Research Consortium
6. Tel Aviv University to spearhead groundbreaking nanotechnology consortium
7. JCVI Researchers, as Part of NIH Human Microbiome Project Consortium, Publish Papers Detailing the Variety and Abundance of Microbes Living on and in the Human Body
8. Pharmaceutical Consortium Selects BioFortis Software to Manage Collaborative Clinical Data and Biobanking Activities
9. Nonprofit Consortium Publishes Review of Skullcap Adulteration
10. Fumio Hirakawa has been awarded with the notable Golden A' Design Award
11. Curemark Awarded New Patent For Treatment Of Drug And Alcohol Addiction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second ... a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, ... from US2020. , US2020’s mission is to change the trajectory of STEM education ...
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface electromyography ... generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter phase ...
Breaking Biology Technology:
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
Breaking Biology News(10 mins):